The future utilization of stem cell therapy for neurodegenerative disease
has been impeded by the limited numbers of stem cells that can be generated
in vitro for transplantation, the potential immune response to the transplanted
cells, and the sparse population of endogenous progenitor cells that exist
in vivo. Thus, in addition to mastering the isolation and molecular
guidance of stem cells, research is focusing on understanding mechanisms
that increase stem cell numbers and survival, and minimize host rejection.
Notch encodes a transmembrane receptor with signaling integral to development
and cancer. Notch signaling occurs through ligand-induced cleavage that frees
the Notch intracellular domain (Nicd) to enter the nucleus and alter
gene expression via tissue-specific transcription factors.1 Among numerous
roles in nervous system development, Notch is imperative in stem cell biology
because its signaling maintains an undifferentiated progenitor population.2,3
However, the exact mechanism by which Notch prevents differentiation to prolong
self-renewal and pluripotency, and its manipulation for therapeutic
applications, has only recently been proposed (Figure 1).
 |
| Figure 1. Hypothesized mechanism of Notch-mediated neural stem cell
expansion in vivo, based on infusion of soluble Notch
ligand in the rat model. In vitro studies in fetal neural stem cells
show that Notch activation by DLL4 induces a cytoplasmic signaling
cascade that preserves fetal neural stem cell pluripotency and encourages
cell expansion through STAT3-dependent Sonic hedgehog (Shh) release.
(adapted from reference 4) |
Androutsellis-Theotokis and colleagues outlined a signaling cascade initiated
by Notch ligands, Delta-like 4 (DLL4) and Jagged 1 (Jag1), that increased
fetal neural stem cell (NSC) survival without inducing differentiation in
vitro.4 This pathway includes the obligate cleavage of Nicd. However, the
rapid timeline of cell expansion indicates that Nicd influences cytoplasmic
effectors rather than, or in addition to, the commonly-associated yet delayed
transcriptional response. Examination of kinase activation and administration
of JAK and p38 kinase inhibitors identified that DLL4 and Jag1 led to activation
of Akt kinase and mammalian target of rapamycin (mTOR). Both are serine/threonine
kinases related to cell proliferation and differentiation, with downstream
phosphorylation of transcription factor STAT3.
Other research has associated Notch signaling and STAT3 activation with differentiation
to a glial cell fate.5-7 This is in apparent contrast to a Notch-dependent preservation
of pluripotency. The discrepancy may be explained by different phosphorlyation
sites. Rather than the previously reported phosphorlyation of STAT3
(Tyr705) that drives glial cell fate,7 Androutsellis-Theotokis et al. discovered
that phosphorylation of STAT3 on Ser727 is integral to Notch-dependent
cell expansion through its upregulation of both the Hes3 transcriptional
repressor and expression of Sonic hedgehog (Shh).4 To further support the
critical contribution of Notch to NSC, Basak and Taylor generated transgenic
mice expressing Hes5-GFP under a Notch1 reporter and correlated the degree
of self-renewal and pluripotency in vitro to the level of Notch1 activity
in the developing nervous system.8 In combination, these results unveil the
multiple paths of Notch influence on stem cell integrity and fate, thus
providing molecular targets to manipulate stem cell populations.
To support their in vitro findings, Androutsellis-Theotokis et al. infused
DLL4 and/or FGF basic into the normal adult rat brain. While FGF basic had
little effect, DLL4 stimulated the proliferation of a subset of cells that
expressed early neuronal markers, but
lacked markers of mature glial cells and neurons.4 Supplementing previous
studies that examined Notch signaling in experimental brain injury,9,10
rats subjected to ischemic injury followed by DLL4 and FGF basic treatment
exhibited improved motor recovery at 45 days post-injury.4 These results
suggest that exogenous stimulation of Notch signaling enhances the endogenous
progenitor cell population. This highlights a potential therapeutic
approach to maximize an innate capacity for self-repair.
References
- Chica, S. (2006) Stem Cells 24:2437.
- Alexson, T.O. et al. (2006) Dev. Neurosci. 28:34.
- Hitoshi, S. et al. (2002) Genes Dev. 16:846.
- Androutsellis-Theotokis, A. et al. (2006) Nature 442:823.

- Tanigaki, K. et al. (2001) Neuron 29:45.
- Jadhav, A.P. et al. (2006) Proc. Natl. Acad. Sci. USA 103:18998.
- Kamakura, S. et al. (2004) Nat. Cell Biol. 6:547.
- Basak, O. & V. Taylor (2007) Eur. J. Neurosci. 25:1006.
- Givogri, M.I. et al. (2006) Dev. Neurosci. 28:81.
- Arumugam, T.V. et al. (2006) Nat. Med. 12:621.

This
symbol denotes references that cite the use of our products. |